




QUARTERLY STATEMENT Q1|2020

JANUARY 1 TO MARCH 31, 2020

STRATEC POSTS DYNAMIC START TO FINANCIAL YEAR 2020

- Sales up by 21.3% to € 56.5 million in Q1/2020; organic growth of +20.1% (Q1/2019: € 46.6 million)
- Adjusted EBIT for Q1/2020 increases by 53.9% to € 7.7 million (Q1/2019: € 5.0 million)
- Adjusted EBIT margin for Q1/2020 up 290 basis points to 13.6% (Q1/2019: 10.7%)
- Significantly higher orders and order forecasts, but also growing supply chain complexity due to COVID-19 pandemic
- Outlook for 2020 confirmed: Organic sales growth in low double-digit percentage range and adjusted EBIT margin of around 15% expected

Dear Shareholders, Partners and Friends of STRATEC,

STRATEC can report a very successful start to financial year 2020. In the first quarter, we generated organic sales growth of 20.1% and increased our adjusted EBIT by 53.9%. In response to these pleasing results, on May 4, 2020 we raised our guidance figure for organic sales growth in financial year 2020. Not only that, we also achieved important milestones in numerous current development projects and reached a well advanced stage of negotiations for new development cooperations. Our development pipeline is still well stocked and offers a superb basis for generating further sustainable growth at our company.

This being said, the first quarter of 2020 was an exceptional period, and that not only for STRATEC. COVID-19 has the world firmly in its grip and we are working flat out to play our part in containing the pandemic. Many of our customers offer relevant tests that are performed on systems designed and manufactured by STRATEC. To be able to support our partners, it is therefore crucial for our company to maintain its full supply capacity. At present, and notwithstanding various challenges, for example within the supply chain, we have managed to do this with great success. We will maintain this course with absolute consistency.

Our management has always accorded the utmost priority to protecting the health of our employees. We therefore took extensive measures in mid-February already in order to avoid infections within our workforce as far as possible.

We welcomed further new employees to the STRATEC Group once again in the first quarter of 2020 and slightly

increased our organic employee totals compared with December 31, 2019. To be able to implement the large number of development projects, we expect to require further highly qualified staff in the years ahead as well.

Moreover, we are delighted, not least in these exceptional times that have once more demonstrated the robustness of our business model, to be able to propose what will already be the sixteenth consecutive increase in our dividend to € 0.84 per share for approval by our shareholders (previous year: € 0.82 per share).

Thank you for the trust you have placed in us.

On behalf of the Board of Management
of STRATEC SE



Marcus Wolfinger
Chief Executive Officer

Key figures¹

€ 000s	Q1/2020 ²	Q1/2019 ²	Change
Sales	56,504	46,569	+21.3 %
Adjusted EBITDA	10,142	7,177	+41.3 %
Adjusted EBITDA margin (%)	17.9	15.4	+250 bps
Adjusted EBIT	7,658	4,975	+53.9 %
Adjusted EBIT margin (%)	13.6	10.7	+290 bps
Adjusted consolidated net income ³	6,246	3,756	+66.3 %
Adjusted earnings per share (€) ³	0.52	0.31	+67.7 %
Earnings per share (€) ³	0.37	0.11	+236.4 %

bps = Basis points

¹ For comparison purposes, adjusted figures exclude amortization resulting from purchase price allocations in the context of acquisitions and the associated reorganization expenses.

² To facilitate comparison, adjusted to account for the disposal of the Data Solutions business unit, which has been reported as a discontinued operation.

³ Result from continuing operations.

BUSINESS PERFORMANCE

STRATEC increased its consolidated sales year-on-year by 21.3% to € 56.5 million in the first quarter of 2020 (Q1/2019: € 46.6 million). Adjusted for exchange rate effects, this corresponds to organic sales growth of 20.1 %. This dynamic sales performance was driven by all segments, while the COVID-19 pandemic, to date, had only a very minor positive impact on the sales performance in the first quarter. Within the Instrumentation segment, the business with service parts and consumables posted a particularly strong performance. System sales also rose substantially compared with the previous year. Diatron generated significant growth, not least in its business with veterinary diagnostics products. In the Smart Consumables segment, both product sales and sales with development and services increased in line with the budget.

Adjusted EBIT increased by 53.9% to € 7.7 million, up from € 5.0 million in the previous year's quarter. As a result, the adjusted EBIT margin improved year-on-year by 290 basis points to 13.6% (Q1/2019: 10.7%). This positive development in the margin was due in particular to positive benefits of scale, as well as to a good sales and product mix.

Given this increase in operating profitability and an additional reduction in the tax rate, consolidated net income from continuing operations increased by 66.3% to € 6.2 million (Q1/2019: € 3.8 million). Adjusted (basic) earnings per share from continuing operations amounted to € 0.52 in the first quarter of 2020, as against € 0.31 in the previous year.

To facilitate comparison, the figures stated above for the first quarter of 2020 and the previous year's figures have been adjusted to account for the disposal of the Data Solutions business unit, which has been reported as a discontinued operation. In the interests of comparability, the key earnings

figures have also been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and associated reorganization expenses. A reconciliation of the adjusted figures with the figures reported in the consolidated income statement is provided below.

€ 000s	01.01. – 03.31.2020	01.01. – 03.31.2019
Adjusted EBIT	7,658	4,975
Adjustments		
• PPA amortization	-2,062	-2,277
• Expenses relating to transactions and associated restructuring expenses	0	-723
EBIT	5,596	1,975

€ 000s	01.01. – 03.31.2020	01.01. – 03.31.2019
Adjusted consolidated net income from continuing operations	6,246	3,756
Adjusted earnings per share from continuing operations in € (basic)	0.52	0.31
Adjustments		
• PPA amortization	-2,062	-2,277
• Expenses relating to transactions and associated restructuring expenses	0	-723
• Taxes on income	320	556
Consolidated net income from continuing operations	4,503	1,312
Earnings per share from continuing operations in € (basic)	0.37	0.11

FINANCIAL GUIDANCE

To account for its strong performance in the first four months and for current order forecasts from its customers, on May 4, 2020 STRATEC published an ad-hoc announcement in which it raised the guidance figure for its organic sales growth in financial year 2020.

Based on adjustments made to the previous year's figures to account for the disposal of the Data Solutions business unit (2019 sales basis: € 214.2 million), STRATEC now expects to generate constant-currency organic sales growth in a low double-digit percentage range. A figure of around 15% is forecast for the adjusted EBIT margin.

In connection with the COVID-19 pandemic, STRATEC is currently observing significantly positive and slightly negative effects in terms of its customer order and order forecasts. Overall, the company currently expects to see a notably positive impact on demand in the current financial year. All in all, the implications of the pandemic, such as those outlined above, but also potential interruptions within the supply chain, are still not fully visible. Apart from those effects that had already materialized by the end of April 2020, the above guidance therefore does not account for the effects of the pandemic.

For 2020, STRATEC has budgeted investments in property, plant and equipment and intangible assets at around 10% to 12% of sales. Investments in property, plant and equipment mainly relate to the construction work currently underway to significantly extend the buildings at the company's headquarters in Birkenfeld. This work is scheduled for completion in the third quarter of 2020. As a result, the investment ratio is expected to decrease further in 2021.


PROJECTS AND OTHER DEVELOPMENTS

Customers launched a number of new products designed by STRATEC onto the market once again in the first quarter of 2020. Examples worth mentioning include significant software and hardware extensions for a molecular diagnostics analyzer system of a North American partner. Among other benefits, these extensions will increase test capacity and further enhance the user-friendliness of the system. Not only that, the KleeYa instrument – STRATEC's proprietary next-generation analyzer platform for chemiluminescence immunoassays – achieved CE conformity.

Given the continuing trend within the in-vitro diagnostics industry to outsource automation solutions to specialist companies such as STRATEC, the company still has a well-filled development pipeline. In the first quarter, STRATEC also made further progress with numerous negotiations for promising future projects.

DEVELOPMENT IN PERSONNEL

In the first quarter, STRATEC once again increased its organic employee totals compared with the previous year. Excluding employees at the Data Solutions business unit, which was sold at the beginning of May 2020, and including personnel hired from a temporary employment agency and trainees, the STRATEC Group had a total of 1,292 employees as of March 31, 2020. This corresponds to organic growth of 3.8% in the workforce compared with December 31, 2019. Due to its ongoing high level of development activity, STRATEC expects to have a growing need for highly qualified staff in the years ahead as well.



CONSOLIDATED BALANCE SHEET

as of March 31, 2020

Assets

€ 000s	03.31.2020	12.31.2019
Non-current assets		
Goodwill	38,729	40,674
Other intangible assets	51,229	56,418
Right-of-use assets	7,858	8,583
Property, plant and equipment	50,402	47,338
Non-current financial assets	427	447
Non-current contract assets	17,395	15,616
Deferred taxes	1,040	1,207
	167,080	170,283
Current assets		
Inventories	58,032	55,978
Trade receivables	39,326	34,121
Current financial assets	1,259	1,319
Current other receivables and assets	8,240	6,124
Current contract assets	5,959	4,780
Income tax receivables	4,346	4,101
Cash and cash equivalents	32,856	22,708
	150,018	129,131
Total assets	317,098	299,414

Shareholders' equity and debt

€ 000s	03.31.2020	12.31.2019
Shareholders' equity		
Share capital	12,030	12,030
Capital reserve	26,708	26,457
Revenue reserves	123,354	120,978
Treasury stock	-89	-89
Other equity	-4,359	-369
	157,644	159,007
Non-current debt		
Non-current financial liabilities	104,417	90,378
Non-current other liabilities	378	481
Non-current contract liabilities	1,837	1,869
Provisions for pensions	5,232	5,077
Deferred taxes	6,748	6,931
	118,612	104,736
Current debt		
Current financial liabilities	12,538	9,584
Trade payables	13,765	12,266
Current other liabilities	7,138	6,016
Current contract liabilities	3,640	4,407
Provisions	1,148	1,138
Income tax liabilities	2,613	2,260
	40,842	35,671
Total shareholders' equity and debt	317,098	299,414

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the Period from January 1 to March 31, 2020

€ 000s	01.01. – 03.31.2020 ¹	01.01. – 03.31.2019 ¹
Sales	56,504	46,569
Cost of sales	-39,836	-36,073
Gross profit	16,668	10,496
Research and development expenses	-2,775	-2,169
Sales-related expenses	-3,145	-2,101
General administration expenses	-5,149	-4,534
Other operating income and expenses	-3	283
Earnings before interest and taxes (EBIT)	5,596	1,975
Net financial expenses	-276	-452
Earnings before taxes (EBT)	5,320	1,523
Taxes on income	-817	-211
Earnings from continuing operations	4,503	1,312
Earnings from discontinued operations	-2,127	-1,628
Consolidated net income	2,376	-316
Items that may be subsequently reclassified to profit or loss:		
Currency translation differences from translation of foreign operations	-3,943	1,266
Other comprehensive income (OCI)	-3,943	1,266
Comprehensive income	-1,567	950
Basic earnings per share in €	0.20	-0.03
from continuing operations	0.37	0.11
from discontinued operations	-0.18	-0.14
No. of shares used as basis (undiluted)	12,025,300	11,964,250
Diluted earnings per share in €	0.20	-0.03
from continuing operations	0.37	0.11
from discontinued operations	-0.18	-0.14
No. of shares used as basis (diluted)	12,070,440	12,021,057

¹ To facilitate comparison, adjusted to account for the disposal of the Data Solutions business unit, which has been reported as a discontinued operation.

CONSOLIDATED STATEMENT OF CASH FLOWS

for the Period from January 1 to March 31, 2020

€ 000s	01.01. – 03.31.2020	01.01. – 03.31.2019
I. Operations		
Consolidated net income (after taxes)	2,376	-316
Depreciation and amortization	7,707	4,605
Current income tax expenses	1,010	873
Income taxes paid less income taxes received	-893	-3,437
Financial income	-13	-11
Financial expenses	315	257
Interest paid	-315	-275
Interest received	13	12
Other non-cash expenses	2,462	2,876
Other non-cash income	-1,738	-788
Change in net pension provisions through profit or loss	157	25
Change in deferred taxes through profit or loss	33	-649
Profit (-)/loss (+) on disposals of non-current assets	0	-22
Increase (-)/decrease (+) in inventories, trade receivables and other assets	-12,419	-6,027
Increase (+)/decrease (-) in trade payables and other liabilities	4,533	12,377
Cash flow from operating activities	3,228	9,500
II. Investments		
Incoming payments from disposals of non-current assets		
• Property, plant and equipment	1	22
• Financial assets	74	30
Outgoing payments for investments in non-current assets		
• Intangible assets	-2,626	-3,073
• Property, plant and equipment	-4,522	-3,911
Incoming payments from sale of companies previously consolidated, less cash funds thereby ceded	0	-871
Cash flow from investing activities	-7,073	-7,803
III. Financing		
Incoming funds from taking up of financial liabilities	22,000	0
Outgoing payments for repayment of financial liabilities	-7,454	-496
Cash flow from financing activities	14,546	-496
IV. Cash-effective change in cash and cash equivalents (net balance of I–III)	10,701	1,201
Cash and cash equivalents at start of period	22,708	24,095
Impact of exchange rate movements	-552	-277
Cash and cash equivalents at end of period	32,856	25,019

FINANCIAL CALENDAR

05 05.14.2020 Quarterly Statement Q1 2020	06 06.08.2020 Annual General Meeting	08 08.13.2020 Half-Year Financial Report H1 2020	11 11.05.2020 Quarterly Statement 9M 2020	11 11.17.2020 German Equity Forum, Frankfurt/Main, Germany
--	--	---	--	---

Subject to amendment.

Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

IMPRINT AND CONTACT

Published by

STRATEC SE
 Gewerbestr. 37
 75217 Birkenfeld
 Germany
 Phone: +49 7082 7916-0
 Fax: +49 7082 7916-999
info@stratec.com
www.stratec.com

Head of Investor Relations & Corporate Communications

Jan Keppeler
 Phone: +49 7082 7916-6515
 Fax: +49 7082 7916-9190
j.keppeler@stratec.com

Notice

Forward-looking statements involve risks: This quarterly statement contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This quarterly statement contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this quarterly statement on account of mathematical rounding up or down in the course of addition.

In this quarterly statement, words in the masculine include words in the feminine; in parts of the quarterly statement, the masculine form has solely been used to make the document easier to read.

This quarterly statement is available in both German and English. Both versions can be downloaded from the company's website at www.stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.